Transdermal delivery of treatment for Alzheimer's disease: Development, clinical performance and future prospects

Drugs and Aging

Volumn 25, Issue 9, 2008, Pages 761-775

  Chan, Agnes L F ^a,b   Chien, Yie W ^a   Jin Lin, Shun ^a  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b CHI MEI MEDICAL CENTER   (Taiwan)

Author keywords

Acetylcholinesterase inhibitors, therapeutic use; Alzheimer's disease, treatment; Estradiol, therapeutic use; Muscarinic receptor agonists, therapeutic use; Nicotine, therapeutic use; Phenserine, therapeutic use; Physostigmine, therapeutic use

Indexed keywords

ESTRADIOL; HOMOTAURINE; LEUPRORELIN; NICOTINE; PHENSERINE; PHYSOSTIGMINE; RIVASTIGMINE; TACRINE; TARENFLURBIL; XALIPRODEN;

ALZHEIMER DISEASE; AREA UNDER THE CURVE; BEHAVIOR DISORDER; CHRONIC DISEASE; COGNITIVE DEFECT; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; MAXIMUM PLASMA CONCENTRATION; NEUROPATHOLOGY; PRIORITY JOURNAL; REVIEW; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, CUTANEOUS; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; ESTROGENS; HUMANS; MUSCARINIC AGONISTS; NICOTINE; SKIN ABSORPTION;

EID: 50249113134     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200825090-00003     Document Type: Review

References (101)

1. Novartis media factsheet. Exelon® patch, a new therapeutic approach [online]. Available from URL: http://www.lif.se/cs/Publik%20webb/Sidinnehall/ Publik_Dokument/Pressmeddelanden/FACTS_ABOUT_THE_EXELON_PATCH.doc [Accessed 2008 Jul 11]
2. Hebert LE, Scherr PA, Bienias JL, et al. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol 2003; 60: 1119-22
3. Chou J. Use your faculties and Alzheimer's can be kept at bay. Taipei Times 2005; 15: 1-2
4. Wimo A, Jonsson L, Winblad B. An estimate of the worldwide prevalence and direct costs of dementia in 2003. Dement Geriatr Cogn Disord 2006; 21: 175-81
5. Darvesh S, Walsh R, Kumar R, et al. Inhibition of human cholinesterases by drugs used to treat Alzheimer disease. Alzheimer Dis Assoc Disord 2003; 17 (2): 117-26
6. Perry EK, Perry RH, Blessed G, et al. Changes in brain cholinesterases in senile dementia of Alzheimer type. Neuropathol Appl Neurobiol 1978; 4: 273-7
7. Silver A. The biology of cholinesterases. Amsterdam: Elsevier, 1974
8. Sikdar S. Should titration schedules for cholinesterase inhibitors be changed? Int J Geriatr Psychiatry 2003; 18: 1063-4
9. Rosler M, Anand R, Cicin-Sain A, et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomized controlled trial. BMJ 1999; 318 (6): 633-40
10. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev 2006; 25 (1): CD005593
11. Winblad B, Cumming J, Andreasen N, et al. A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease: rivastigmine patch versus capsule. Int J Geriatr Psychiatry 2007; 32 (5): 456-67
12. Utsuki T, Uchimura N, Irikura M, et al. Preclinical investigation of the topical administration of phenserine: transdermal flux, cholinesterase inhibition, and cognitive efficacy. J Pharmacol Exp Ther 2007; 321 (1): 353-61
13. Davis B. Circadian cholinergic rhythms: implications for cholinesterase inhibitor therapy. Dement Geriatr Cogn Disord 2006; 21 (2): 120-9
14. Transdermal drug delivery systems. In: Allen Jr LV, Popovich NG, Ansel HC. Ansel's pharmaceutical dosage forms and drug delivery systems. 8th ed. Philadelphia (PA): Lippincott Williams and Willkins, 2004: 298-315
15. Moller HJ, Hampel H, Hegerl U, et al. Double-blind, randomized, placebo-controlled clinical trial on the efficacy and tolerability of a physostigmine patch in patients with senile dementia of the Alzheimer type. Pharmacopsychiatry 1999; 32: 99-106
16. Jaskari T, Vuorio M, Kontturi K, et al. Controlled transdermal iontophoresis by ion-exchange fiber. J Control Release 2000; 67 (2-3): 179-90
17. Benech H, Vincenti M, Fouchart F, et al. Development and in vivo assessment of a transdermal system for physostigmine. Methods Find Exp Clin Pharmacol 1998; 20 (6): 489-98
18. Kankkunen T, Sulkava R, Vuorio M, et al. Transdermal iontophoresis of tacrine in vivo. Pharm Res 2002; 19: 705-8
19. Wagstaff AJ, McTavish D. Tacrine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in Alzheimer's disease. Drugs Aging 1994; 4 (6): 510-40
20. Lefèvre G, Sedek G, Jhee SS, et al. Pharmacokinetics and pharmacodynamics of the novel daily rivastigmine transdermal patch compared with twice-daily capsules in Alzheimer's disease patients. Clin Pharmacol Ther 2008; 83: 106-14
21. Jann MW, Shirley KL, Small GW. Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors. Clin Pharmacokinet 2002; 41 (10): 719-39
22. Howe MN, Price IR. Effects of transdermal nicotine on learning, memory, verbal fluency, concentration, and general health in a healthy sample at risk for dementia. Int Psychogeriatr 2001; 13: 465-75
23. White HK, Levin ED. Four-week nicotine skin patch treatment effects on cognitive performance in Alzheimer's disease. Psychopharmacology 1999; 143: 158-65
24. Levin ED, Simon BB, Conners CK. Nicotine effects and attention-deficit/ hyperactivity disorder. In: Piasecki M, Newhouse PA, editors. Nicotine in psychiatry: psychopathology and emerging therapeutics. Washington, DC: American Psychiatric Press 2000: 203-14
25. Levin ED, Rezvani AH. Nicotinic treatment for cognitive dysfunction. Curr Drug Targets CNS Neurol Disord 2002; 1 (4): 423-31
26. Henderson V, Paganini-Hill A, Emanuel C, et al. Estrogen replacement therapy in older women: comparison between Alzheimer's disease cases and nondemented control subjects. Arch Neurol 1994; 51: 896-900
27. Baldereschi M, Di-Carlo A, Lepore V, et al. Estrogen-replacement therapy and Alzheimer's disease in the Italian Longitudinal Study on Aging. Neurology 1998; 50: 996-1002
28. Hogervorst E, Yaffe K, Richards M, et al. Hormone replacement therapy for cognitive function in postmenopausal women. Cochrane Database Syst Rev 2002; (3): CD003122
29. Wenk GL. Neuropathologic changes in Alzheimer's disease. J Clin Psychiatry 2003; 64 Suppl. 9: 7-10
30. Tiraboschi P, Hansen LA, Thal LJ, et al. The importance of neuritic plaques and tangles to the development and evolution of AD. Neurology 2004; 62 (11): 1984-9
31. Scarpini E, Scheltens P, Feldman H. Treatment of Alzheimer's disease: current status and new perspectives, Lancet Neurol 2003; 2: 539-47
32. Walker LC, Rosen RF. Alzheimer therapeutics: what after the cholinesterase inhibitors? Age Ageing 2006; 35: 332-5
33. Shen J, Kelleher 3rd RJ. The presenilin hypothesis of Alzheimer's disease: evidence for a loss-of-function pathogenic mechanism. Proc Natl Acad Sci U S A 2007; 102 (2): 403-9
34. Mikiciuk-Olasik E, Szymanski P, Zurek E. Diagnostics and therapy of Alzheimer's disease. Indian J Exp Biol 2007; 45 (4): 315-25
35. Iqbal K, Flory M, Khatoon S, et al. Subgroups of Alzheimer's disease based on cerebrospinal fluid molecular markers. Ann Neurol 2005; 58: 748-57
36. Andorfer C, Acker CM, Kress Y, et al. Cell-cycle reentry and cell death in transgenic mice expressing nonmutant human tau isoforms. J Neurosci 2005; 25: 5446-54
37. Schmitz C, Rutten B, Pielen A, et al. Hippocampal neuron loss exceeds amyloid plaque load in a transgenic mouse model of Alzheimer's disease. Am J Pathol 2004; 164 (4): 1495-502
38. Nistor M, Don M, Parekh M, et al. Alpha- and beta-secretase activity as a function of age and beta-amyloid in Down syndrome and normal brain. Neurobiol Aging 2007; 28 (10): 1493-506
39. Lott I, Head E. Alzheimer disease and Down syndrome: factors in pathogenesis. Neurobiol Aging 2005; 26 (3): 383-9
40. Yankner B, Duffy L, Kirschner D. Neurotropic and neurotoxic effects of amyloid beta protein: reversal by tachykinin neuropeptides. Science 1990; 250: 279-82
41. Blanchard BJ, Hiniker AE, Lu CC, et al. Elimination of amyloid beta neurotoxicity. J Alzheimers Dis 2000; 2 (2): 137-49
42. Venezia V, Nizzari M, Carlo P, et al. Amyloid precursor protein and presenilin involvement in cell signaling. Neurodegener Dis 2007; 4 (2-3): 101-11
43. Lee KH, Shin BH, Shin KJ, et al. A hybrid molecule that prohibits amyloid fibrils and alleviates neuronal toxicity induced by beta-amyloid (1-42). Biochem Biophys Res Commun 2005; 328 (4): 816-23
44. Lacor PN, Buniel MC, Chang L, et al. Synaptic targeting by Alzheimer's-related amyloid beta oligomers. J Neurosci 2004; 24 (45): 10191-200
45. Siegel SJ, Bieschke J, Powers ET, et al. The oxidative stress metabolite 4-hydroxynonenal promotes Alzheimer protofibril formation. Biochemistry 2007; 46 (6): 1503-10
46. Richartz E, Batra A, Simon P, et al. Diminished production of proinflammatory cytokines in patients with Alzheimer's disease. Dement Geriatr Cogn Disord 2005; 19: 184-8
47. Arosio B, Trabattoni D, Galimberti L, et al. Interleukin-10 and interleukin-6 gene polymorphisms as risk factors for Alzheimer's disease. Neurobiol Aging 2004; 25: 1009-15
48. Remarque EJ, Bollen EL, Weverling-Rijnsburger AW, et al. Patients with Alzheimer's disease display a pro-inflammatory phenotype. Exp Gerontol 2001; 36: 171-6
49. Guerreiro RJ, Santana I, Bras JM, et al. Peripheral inflammatory cytokines as biomarkers in Alzheimer's disease and mild cognitive impairment. Neurodegener Dis 2007; 4 (6): 406-12
50. Zekanowski C, Religa D, Graff C, et al. Genetic aspects of Alzheimer's disease. Acta Neurobiol Exp (Wars) 2004; 64 (1): 19-31
51. Butterfield DA, Poon HF, Clair DS, et al. Redox proteomics identification of oxidatively modified hippocampal proteins in mild cognitive impairment: insights into the development of Alzheimer's disease. Neurobiol 2006; 22: 223-32
52. Butterfield DA, Reed T, Perluigi M, et al. Elevated protein-bound levels of the lipid peroxidation product, 4-hydroxy-2-nonenal, in brain from persons with mild cognitive impairment. Neurosci Lett 2006; 397: 170-3
53. Schipper HM, Bennett DA, Liberman A, et al. Glial heme oxygenase-1 expression in Alzheimer disease and mild cognitive impairment. Neurobiol 2006; 27: 252-61
54. Raina AK, Zhu X, Rottkamp CA, et al. Cyclin' toward dementia: cell cycle abnormalities and abortive oncogenesis in Alzheimer disease. J Neurosci Res 2000; 61 (2): 128-33
55. McShea A, Lee HG, Petersen RB, et al. Neuronal cell cycle reentry mediates Alzheimer disease-type changes. Biochim Biophys Acta 2007; 1772: 467-72
56. Chen X, Stern D, Yan SD. Mitochondrial dysfunction and Alzheimer's disease. Curr Alzheimer Res 2006; 3 (5): 515-20
57. Chen X, Yan SD. Mitochondrial Abeta: a potential cause of metabolic dysfunction in Alzheimer's disease. IUBMB Life 2006; 58 (12): 686-94
58. Mancuso M, Coppede F, Murri L, et al. Mitochondrial cascade hypothesis of Alzheimer's disease: myth or reality? Antioxid Redox Signal 2007; 9 (10): 1631-46
59. Alzheimer's disease [online]. Available from URL: http://en.wikipedia. org/wiki/Alzheimer's_disease [Accessed 2007 Jul 28]
60. Asthana S, Craft S, Baker LD, et al. Cognitive and neuroendocrine response to transdermal estrogen in postmenopausal women with Alzheimer's disease: results of a placebo-controlled, double-blind, pilot study. Psychoneuroendocrinology 1999; 24 (6): 657-77
61. Mercier F, Lefèvre G, Huang HL, et al. Rivastigmine exposure provided by a transdermal patch versus capsules. Curr Med Res Opin 2007 Dec; 23 (12): 3199-204
62. Morrow T. Transdermal patches are more than skin deep. Manag Care 2004; 13 (4): 50-1
63. Greig NH, Ruckle J, Comer P, et al. Anticholinesterase and pharmacokinetic profile of phenserine in healthy elderly human subjects. Curr Alzheimer Res 2005; 2 (4): 483-92
64. Sathyan G, Ritschel WA, Hussain AS. Transdermal delivery of tacrine: I. Identification of a suitable delivery vehicle. Int J Pharm 1995; 114: 75-83
65. Fishman DL. Computerized Clinical Information System (CCIS). Wilton (CT): Micromedex Inc. Online Inc., 2006
66. Greig NH, De Micheli E, Holloway HW, et al. The experimental Alzheimer drug phenserine: preclinical pharmacokinetics and pharmacodynamics. Acta Neurol Scand Suppl 2000; 176: 74-84
67. Utsuki T, Uchimura N, Irikura M, et al. Pre-clinical investigation of the topical administration of phenserine: transdermal flux cholinesterase inhibition and cognitive efficacy. J Pharmacol Exp Ther 2007; 321 (1): 353-61
68. Lefèvre G, Sedek G, Huang HA, et al. Pharmacokinetics of a rivastigmine transdermal patch formulation in healthy volunteers: relative effects of body site application. J Clin Pharmacol 2007; 47: 471-8
69. Mercier F, Lefèvre G, Huang HL, et al. Rivastigmine exposure provided by a transdermal patch versus capsules. Curr Med Res Opin 2007 Dec; 23 (12): 3199-204
70. Cummings J, Lefèvre G, Small G, et al. Pharmacokinetic rationale for the rivastigmine patch. Neurology 2007; 69: S10-3
71. Winblad B, Kawata AK, Beusterien KM, et al. Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer's disease. Int J Geriatr Psychiatry 2007; 22 (5): 485-91
72. 2 rivastigmine patch in patients with Alzheimer's disease (ADEPT) [online]. Available from URL: http://clinicaltrials.gov/ct2/show/NCT00561392 [Accessed 2008 Jul 13]
73. 2 patch in patients with Alzheimer's disease (AD) showing cognitive decline [online]. Available from URL: http://clinicaltrials.gov/ct2/show/NCT00506415 [Accessed 2008 Jul 13]
74. Spencer JP, Weil A, Hill K, et al. Transgenic mice overexpressing human beta-amyloid have functional nicotinic alpha 7 receptors. Neuroscience 2006; 137 (3): 795-805
75. Rosato SM, Cattaneo A, Cherubini E. Nicotine-induced enhancement of synaptic plasticity at CA3-CA1 synapses requires GABAergic interneurons in adult anti-NGF mice. J Physiol 2006; 576 Pt 2: 361-77
76. Wilson AL, Langley LK, Monley J, et al. Nicotine patches in Alzheimer's disease: pilot study on learning, memory, and safety. Pharmacol Biochem Behav 1995; 51: 509-14
77. Hogg RC, Bertrand D. Partial agonists as therapeutic agents at neuronal nicotinic acetylcholine receptors. Biochem Pharmacol 2007; 73 (4): 459-68
78. Messer Jr WS. The utility of muscarinic agonists in the treatment of Alzheimer's disease. J Mol Neurosci 2002; 19 (1-2): 187-93
79. Fisher A, Brandeis R, Bar-Ner RH, et al. AF150(S) and AF267B: M1 muscarinic agonists as innovative therapies for Alzheimer's disease. J Mol Neurosci 2002; 19 (1-2): 145-53
80. Frederick B, Satlin A, Wald LL, et al. Brain proton magnetic resonance spectroscopy in Alzheimer disease: changes after treatment with xanomeline. Am J Geriatr Psychiatry 2002; 10 (1): 81-8
81. Bodick NC, Offen WW, Levey AI, et al. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. Arch Neurol 1997; 54 (4): 465-73
82. Mirza NR, Peters D, Sparks RG. Xanomeline and the antipsychotic potential of muscarinic receptor subtype selective agonists. CNS Drug Rev 2003; 9 (2): 159-86
83. Green PS, Simpkins JW. Estrogens and estrogen-like non-feminizing compounds: their role in the prevention and treatment of Alzheimer's disease. Ann N Y Acad Sci 2000; 924: 93-8
84. Yaffe K, Vittinghoff E, Ensrud KE, et al. Effects of ultra-low-dose transdermal estradiol on cognition and health-related quality of life. Arch Neurol 2006; 63 (7): 945-50
85. Almeida OP, Lautenschlager NT, Vasikaran S, et al. A 20-week randomized controlled trial of estradiol replacement therapy for women aged 70 years and order: effecting mood, cognition and quality of life. Neurobiol Aging 2006; 27 (1): 141-9
86. Hogervorst E, Yaffe K, Richards M, et al. Hormone replacement therapy to maintain cognitive function in women with dementia. Cochrane Database Syst Rev 2002; (3): CD003799
87. Effects of estrogen on memory in post-menopause women and patients with Alzheimer's disease [online]. Available from URL: http://www.clinicaltrials.gov/ ct2/results?.term=estrogen+AND+alzheimer%27s+disease [Accessed 2007 Jul 29]
88. Hall KA, Keks NA, O'Connor DW. Transdermal estrogen patches for aggressive behavior in male patients with dementia: a randomized, controlled trial. Int Psychogeriatr 2005; 17 (2): 165-78
89. Corbo RM, Gambina G, Ruggeri M, et al. Association of estrogen receptor alpha (ESR1) Pvull and Xbal polymorphisms with sporadic Alzheimer's disease and their effect on apolipoprotein E concentrations. Dement Geriatr Cogn Disord 2006; 22 (1): 67-72
90. Monastero R, Cefalu AB, Camarda C, et al. Association of estrogen receptor alpha gene with Alzheimer's disease: a case-control study. J Alzheimers Dis 2006; 9 (3): 273-8
91. Porrello E, Monti MC, Sinforiani E, et al. Estrogen receptor alpha and APOEepsilon4 polymorphisms interact to increase risk for sporadic AD in Italian females. Eur J Neurol 2006; 13 (6): 639-44
92. Luckhaus C, Sand PG. Estrogen receptor 1 gene (ESR1) variants in Alzheimer's disease: results of a meta-analysis. Aging Clin Exp Res 2007; 19 (2): 165-8
93. Chopda G. Transdermal drug delivery systems: a review, 2006 [online]. Available from URL: http://www.pharmainfo.net/exclusive/reviews/ transdermal_drug_delivery_systems_:_a_review/ [Accessed 2007 Jul 29]
94. Chien YW, Lin S. Optimization of treatment by applying programmable rate-controlled drug delivery technology. Clin Pharmacokinet 2002; 41 (15): 1267-99
95. Muhlack S, Przuntek H, Miller T. Transdermal rivastigmine treatment does not worsen impaired performance of complex motions in patients with Alzheimer's disease. Pharmacopsychiatry 2006; 39: 16-9
96. Cummings J. A transdermal patch in Alzheimer disease. Neurology 2007; 69 Suppl. 1: S2-3
97. Lemaire L, Fournier J, Ponthus C, et al. Magnetic resonance imaging of the neuroprotective effect of xaliproden in rats. Invest Radiol 2002; 37 (6): 321-7
98. Santa-Maria I, Hernández F, Del Rio J, et al. Tramiprosate, a drug of potential interest for the treatment of Alzheimer's disease, promotes an abnormal aggregation of tau. Mol Neurodegener 2007; 2: 17. Epub 2007 Sep 6
99. Targum SD. Biomarkers for the identification and treatment of dementia: psychiatry MMC [online]. Available from URL: http://www.psychiatrymmc.com/ biomarkers-for-the-identification-and-treatment-of-dementia/ [Accessed 2008 Jul 13]
100. Hone J. Alzheimer's disease: the facts [online]. Available from URL: http://www.pharmatimes.com/subscribe [Accessed 2008 Jul 13]
101. Wang Y, Thakur R, Fan Q, et al. Transdermal iontophoresis: combination strategies to improve transdermal iontophoretic drug delivery. Eur J Pharm Biopharm 2005; 60: 179-91